Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore various work from home opportunities that can help you earn quick cash. Find flexible options that fit your schedule.
23,704 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Microsoft has faced a recent pullback, but the company’s cloud, AI, and productivity strengths create a path to meani...
The latest quarterly results sparked a sharp drop in MercadoLibre shares. In this guide, we unpack why the stock just...
Investors are weighing Amazon's retail muscle against cloud and AI competition. This guide asks: could amazon actuall...
Microsoft is staring down a tough start to the year. Is the slide a red flag or a rare chance to buy a tech titan wit...
This article dives into exagen (XGN) 2026 earnings, unpacking Q1 results, business momentum, and the path to full-yea...
Tuesday brought a notable wobble for the Nasdaq-100, leading the market’s tech retreat. This article breaks down the ...
As Wrap Technologies moves through 2026, the Q1 results shed light on demand for its WRAP security platform. This gui...
Rocket Lab stock has hit an all-time high, but savvy investors know a rally is more than a headline. This guide break...
If you’re chasing reliable income from utilities, you’ll want a clear read on Duke Energy versus Dominion Energy. Thi...
Wall Street’s bearish take on Plug Power stock has critics unsure. This article builds a practical bull case, showing...
Two essential infrastructure players—GE Vernova and Vertiv—sit behind the scenes of AI and modern tech. This guide ex...